A study of the safety, tolerability, and pharamcokinetics of MORAb-003, a humanized monoclonal antibody, in subjects with advanced ovarian cancer
Phase of Trial: Phase I
Latest Information Update: 02 Aug 2013
At a glance
- Drugs Farletuzumab (Primary)
- Indications Ovarian cancer
- Focus Adverse reactions
- Sponsors Eisai Inc; Morphotek
- 02 Dec 2008 Actual end date (Dec 2007) added as reported by ClinicalTrials.gov.
- 02 Dec 2008 Actual start date (Jun 2005) added as reported by ClinicalTrials.gov.
- 02 Dec 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.